Theoretical and experimental validation of dual rhenium radioisotope production for enhanced targeted cancer therapy

For many years, different ligands have been combined with rhenium therapeutic radioisotopes, specifically rhenium-186 and 188, to create radiopharmaceuticals for the treatment of various illnesses. Because of the unique qualities that set each of these radioisotopes apart, they can all be used to eradicate different kinds of cancers. Large cancers can be effectively removed in 188Re thanks to the use of great-energy, long-distance beta particles. However, 186 Re's short range, low energy beta particles are a sufficient weapon to destroy tiny tumors with a high yield and little side effects. As a result, the properties of each of these radioisotopes can only partially address the therapy on their own. Therefore, we reasoned that 188 Re and 186 Re in conjunction must provide the greatest results when treating tumors of different sizes. One possible outcome of neutron-irradiation of natural rhenium is the simultaneous production of 186 Re and 188 Re. We want to know if the natural irradiation of rhenium, together with the simultaneous synthesis of these radioisotopes, provides us with the right amounts of radioactivity to make compositional radiopharmaceuticals. This study examines the kind and quantity of impurities created, as well as the practical and theoretical evaluations of the simultaneous generation of 188 Re and 186 R to achieve compositional radiopharmaceuticals by neutron irradiation of natural rhenium in 5MWt pool-type light water research reactor. The outcomes demonstrated that the theoretical computations and experimental data correlate well. The data's greatest relative error has been determined to be 8%. The findings shown that 186 Re and 188 Re could be produced simultaneously with suitable and almost equal activities with irradiating natural rhenium for 100-120 hours and considering 24 hours for cooling. Also, the levels of impurities in the simultaneous manufacture of 186 Re and 188 Re using the neutron irradiation of natural rhenium are negligible in comparison to the primary products, and the primary products' activities are sufficient to make compositional radiopharmaceuticals. • Simultaneous production of ˆ186ˆRe and ˆ188ˆRe via neutron irradiation of natural rhenium. • Optimal 4-day irradiation yields near-equal activities for combined radiopharmaceuticals. • Low impurities (<0.02% activity) enable high-purity therapeutic formulations. • Theoretical-experimental validation confirms accurate activity predictions. • Dual-isotope approach enhances tumor targeting across varying sizes.